Assessing the value of coronary artery computed tomography as the first-line anatomical test for stable patients with indications for invasive angiography due to suspected coronary artery disease. Initial cost analysis in the CAT-CAD randomized trial

• Published in: Journal of cardiovascular computed tomography Vol. 14; no. 1; pp. 75 - 79
• Main Authors: Rudziński, Piotr Nikodem, Kruk, Mariusz, Kępka, Cezary, Schoepf, U. Joseph, Otani, Katharina, Leonard, Tyler J., Dębski, Mariusz, Dzielińska, Zofia, Pręgowski, Jerzy, Witkowski, Adam, Rużyłło, Witold, Demkow, Marcin
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.01.2020
• Subjects: Computed tomography; Coronary artery disease; Coronary computed tomography angiography; Invasive coronary angiography; Percutaneous coronary intervention; Percutaneous coronary intervention; Computed tomography; Coronary artery disease; Invasive coronary angiography; Coronary computed tomography angiography
• ISSN: 1934-5925; 1876-861X
• DOI: 10.1016/j.jcct.2019.07.008

Clinical and safety outcomes of the strategy employing coronary computed tomography angiography (CCTA) as the first-choice imaging test have recently been demonstrated in the recently published CAT-CAD randomized, prospective, single-center study. Based on prospectively collected data in this patient population, we aimed to perform an initial cost analysis of this approach. 120 participants of the CAT-CAD trial (age:60.6 ± 7.9 years, 35% female) were included in the analysis. We analyzed medical resource use during the diagnostic and therapeutic episode of care. We prospectively estimated the cumulative cost for each strategy by multiplying the number of resources by standardized costs in accordance to medical databases and the 2015 Procedural Reimbursement Payment Guide. The total cost of coronary artery disease (CAD) diagnosis was significantly lower in the CCTA group as compared to the direct invasive coronary angiography (ICA) group ($50,176 vs $137,032) with corresponding per-patient cost of $836 vs $2,284, respectively. Similarly, the entire diagnostic and therapeutic episode of care was significantly less expensive in the CCTA group ($227,622 vs $502,827) with corresponding per-patient cost of $4630 vs $8,380, respectively. Overall, the application of CCTA as a first-line diagnostic test in stable patients with indications to ICA resulted in a 63% reduction of CAD diagnosis costs and a 55% reduction composite of diagnosis and treatment costs during 90-days follow-up. Application of CCTA as the first-line anatomic test in patients with suspected significant CAD decreased the total costs of diagnosis. This is likely attributable to reduced numbers of invasive tests and hospitalisations. Initial cost analysis of the CAT-CAD randomized trial suggests that this approach may provide significant cost savings for the entire health system.